Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food ...

AI has shown promise by analysing data from patient records to recognise complex patterns within large datasets, which can aid in the ...

To evaluate the influence of environmental factors and prematurity relating to juvenile dermatomyositis (JDM), its course and refractoriness to treatment. Maternal exposure to occupational pollutants ...

Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on CRBP stock, giving a Buy rating yesterday. Graig ...

The drug – called brepocitinib – is the centrepiece of the new biotech's R&D pipeline and is already a pair of pivotal trials in patients with dermatomyositis and systemic lupus erythematosus ...

Two other patients with dermatomyositis and diffuse cutaneous systemic sclerosis ... enhancement and hypokinesia detected by cardiac MRI was markedly reduced after treatment with corticosteroids and ...

Lupus is a chronic autoimmune disorder that triggers inflammation in organs and joints, affects mobility, impacts skin health ...

The relationship between Anthony Jennings and Jam Villanueva once again reached the rumor mills, after the latter alluded to ...

Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis ... delayed graft function, ...

Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis ... delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and ...